New Advances in HER2, FGFR4, and PD-1 Solid Tumor Therapies

BeiGene’s TEVIMBRA earned a positive EU opinion for nasopharyngeal cancer, showing strong survival benefits. Bayer’s sevabertinib and Abbisko’s irpagratinib advanced with U.S. and China designations, respectively. China approved trastuzumab rezetecan, its first homegrown HER2-ADC. AstraZeneca’s Imfinzi nears EU approval for bladder cancer. Meanwhile, BLA for patritumab deruxtecan was withdrawn. Other highlights include fast-track status for Candel’s CAN-2409 and Singapore’s EBC-129, plus Clarity’s Phase 3 prostate cancer trial. Astellas struck a $1.47B ADC deal, and subcutaneous Opdivo won EU approval.

Видео New Advances in HER2, FGFR4, and PD-1 Solid Tumor Therapies канала LucidQuest